Difficulty of inclusions and a sufficient number of relevant clinical information

Primary objectives :

• To investigate the safety and the tolerability of ATO by IV infusions to patients with SLE,
• To determine the maximum tolerated dose of ATO.

Secondary objectives :

• Evaluation of the clinical and biological response of the SLE to ATO,
• Time of relapse in case of positive response,
• Determination of the efficacy,
• Pharmacokinetic study of ATO.

Inclusion Criteria:

• Systemic Lupus meeting the ACR (American College of Rheumatology) criteria, progressive either SLEDAI activity score ≥ 4, despite a corticosteroid therapy ≥ 10 mg / d associated with hydroxychloroquine (in the absence of contraindication or intolerance) and / or an immunosuppressive treatment at a stable dose,
• Insured,
• Availability for hospitalization required by the protocol (conventional and daily hospitalizations).

Exclusion Criteria:

• Inability to give their signed informed consent form,
• Performans status > 2
• QTcorrected space before treatment > 0.45 seconds
• Hemoglobin less than 11g/dL
• Neutrophils rate below 1 200 / mm3
• Platelets rate below 100 Giga / mm3
• Previous history of arrhythmia or heart rhythm disorder or other rhythm trouble by referring cardiologist
• Heart disorder (progressive pericarditis, valvular disease, ...) according to cardiologist
• Family previous history of arrhythmias
• Taking drugs that potentially prolong the QT
• Hypersensitivity to the active substance of Trisenox® or any of the excipients
• Serum potassium ≤ 4 milliequivalent / L
• Magnesemia ≤ 1,8 mg / dl
• Increase corticosteroids beyond 20 mg / day within 15 days before inclusion
• Immunosuppressive treatments, thalidomide introduced within the last 3 months
• Biotherapy (rituximab, belimumab, ...) introduced within 6 months prior to inclusion
• Pregnancy or lactation
• For women of childbearing age, men and their partner : unless effective contraception for the duration of participation in the study that is 7 months
• Creatinine clearance <50 ml / min,
• Hepatocellular insufficiency (TP <50%), and / or AST (aspartate aminotransferase) / ALT (alanine aminotransferase) / ALP (alkaline phosphatase) > 2N
• HBsAg positive, DNA detectable HbS
• Infection with HIV, HBV (hepatitis B virus) or HCV (hepatitis C virus)
• Renal or progressive central neurological impairment with possible alternative therapeutic (to be discussed with the principal investigator and scientific board meeting)
• Peripheral neuropathy
• Unweaned alcoholism
• Minor
• Patients older than 65 years
• Patient having been professionally exposed to arsenic (cleaning electronic circuits for example)
• Guardianship patients